CELC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Celcuity is not a strong buy right now for a Beginner with a long-term horizon, despite the bullish analyst tone and strong company-specific clinical progress. The stock has already moved sharply higher and looks technically overbought, so I would not call it a good fresh entry at the current price of 108.07. If the investor is impatient and wants to act now, the better answer is hold rather than chase.
CELC is in an upward trend, with MACD histogram positive and expanding, which supports bullish momentum. However, RSI_6 is 84.471, which is deeply overbought and suggests the recent run may be extended. Moving averages are converging, indicating the trend is not cleanly accelerating from a low-risk base. Price is near resistance at 106.125 and below R2 at 112.206, so upside exists but the current level is not an attractive low-risk entry. The recent trend model also points to weakness over the next week and month, which argues against buying aggressively right now.
Recent analyst commentary remains broadly positive, with multiple firms keeping Buy/Overweight ratings despite trimming price targets after ASCO/VIKTORIA-1 updates. Analysts still see a path to value creation from gedatolisib, including possible launch potential and future label expansion. The company also appears to benefit from continued clinical catalysts in 2026, which can keep sentiment constructive. There is also supportive options positioning with call-heavy flow.
The latest analyst revisions show a downward reset in price targets after ASCO data, reflecting disappointment around the triplet versus doublet readout and some safety concerns. Technicals are stretched, with RSI indicating overbought conditions. The stock trend model suggests negative near-term performance probabilities. News flow provided is mostly unrelated FDA activity, so there is no fresh company-specific news catalyst in the dataset. No significant insider, hedge fund, or congress trading support is visible.
Financial data for the latest quarter was not available due to an error in the provided snapshot, so there is no reliable quarter-by-quarter revenue or earnings assessment here. As a result, I cannot confirm operating growth trends from the current dataset. The investment case is therefore being driven mainly by clinical progress and sentiment rather than fundamentals.
Wall Street remains bullish overall, but the tone has become more mixed recently. In early June 2026, several firms lowered price targets after ASCO/VIKTORIA-1 results, including Craig-Hallum to 171 from 189, Wells Fargo to 166 from 183, and H.C. Wainwright to 145 from 185, while keeping Buy/Overweight ratings. Earlier in May, Stifel, Wells Fargo, Craig-Hallum, Needham, and Guggenheim had raised targets materially and maintained positive ratings. The pros view: strong efficacy potential, practice-changing data, and a credible launch path. The cons view: triplet safety and incremental benefit concerns, plus a post-data valuation reset. Overall, analysts are still positive, but the price target trend has softened recently.
